Management of patients with liver derangement during the COVID-19 pandemic: position statement from the Asia-Pacific Working Group for Liver Derangement

Statement includes use of pharmacological treatment for COVID-19 in the case of liver derangement; and management of patients with chronic hepatitis B or C, non-alcoholic fatty liver disease, liver cirrhosis, and liver transplantation during the pandemic.


Lancet Gastroenterology and Hepatology